Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Pharma
Merck set to advance Winrevair to phase 3 in new indication
Results from a proof-of-concept study of Merck’s Winrevair pave the way for further study of the activin signaling inhibitor in the potential new use.
Kevin Dunleavy
Nov 18, 2025 11:22am
Merck nabs updated FDA label for PAH med Winrevair
Oct 27, 2025 11:37am
Merck releases results from successful trial of Winrevair
Sep 30, 2025 8:00am
Inhibikase taps Pfizer, Gilead alum as CCO to prep PAH launch
Aug 19, 2025 12:11pm
Insmed's phase 2 PAH win sends stock soaring
Jun 10, 2025 11:59am
Merck's Winrevair cuts death, morbidity risk by 76%
Mar 31, 2025 10:00am
